Overview

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC